Eupraxia Pharmaceuticals lost $15.2 million last quarter, up from $6.4 million a year earlier, mainly because of rising research costs.

EPRX · Eupraxia Pharmaceuticals Inc.

The AI's read

The wider loss came from higher research costs for the expanding RESOLVE trial and higher office costs. That spending supported trial work but also increased the loss. The cash and investments are expected to fund operations into the second half of 2028. These facts point in different directions, leaving the company outlook mixed.